The purpose of this study is to evaluate the clinical benefit and safety of an investigational drug for treating refractory head and neck cancer. One of these drugs has been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for some types of cancer including specific types of head and neck cancer. The other drug has been approved for metastatic melanoma, either by itself or in combination with the first drug. Although approved for these purposes, the drug is still being evaluated for its safety and effectiveness in treating Head and Neck cancer, and therefore is considered investigative for this study. There are 2 different combination treatments being investigated in this clinical study:
- Investigational drug + one drug (that is clinically approved to treat Head and Neck cancer)
- One drug that is clinically approved to treat Head and Neck Cancer
If participating in this study, you have a 67% chance of receiving the treatment in (1) above, and a 33% chance for (2).
Who can participate?
We are looking for males and females, aged 18 years or older, who are diagnosed with refractory head and neck cancer. To find out if the study may be suitable for you, please click on the button below and answer the questions.
There are other criteria that need to be fulfilled to be able to take part in the study. If you may pre-qualify, you and a doctor at the study clinic will determine if this study is suitable for you.
What is required from me as a participant?
Before the study begins, you will visit the clinic for screening, where you will be asked to read and sign an informed consent before any study-related procedures are performed. Tests are performed to determine if you qualify to participate in the study.
During the study, you will visit the clinic periodically for treatment and/or clinical evaluations and tests. This may be on a weekly basis, every other week, or once a month, depending on which stage of the study you are in.
More information about study participation
Participating in the study will not entail any extra expense to your usual treatment, as the Sponsor provides the investigational drug and any tests required by the trial. The usual treatment costs will be financed by the National Health Service, by your insurance company, or by yourself.
